Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency

@article{Svensson2003OralAO,
  title={Oral administration of the growth hormone secretagogue NN703 in adult patients with growth hormone deficiency},
  author={Johan Svensson and John P. Monson and Thorsten Vetter and Troels Krarup Hansen and Rachel Savine and Peter Herbert Kann and Mieke Bex and Martin Reincke and Claus Hagen and Albert Beckers and Mbelenge Mapoko Ilondo and M Jasmina Zdravkovic and Bengt-{\aa}ke Bengtsson and M{\'a}rta Korbonits},
  journal={Clinical Endocrinology},
  year={2003},
  volume={58}
}
objective Little is known of the usefulness of GH secretagogues (GHSs) in GH‐deficient (GHD) adults. The objective of this study was to determine the number of responders to treatment with NN703 in GHD adults. 
Growth hormone secretagogues: history, mechanism of action, and clinical development
TLDR
This review will focus on the research history and the pharmacology of each GHS, which reached randomized clinical trials, and highlight the publicly disclosed clinical trials regarding GHSs.
Role of ghrelin in growth hormone-deficient patients
TLDR
Even though ghrelin does not seem to be abnormal in patients with classic GHD, these patients constitute an interesting model for studying GH- and adrenocorticotropic hormone-independent effects of gh Relin.
[Ghrelin and growth hormone secretagogues (GHS): modulation of growth hormone secretion and therapeutic applications].
TLDR
The available data on the discovery of this peptide, the mechanisms of action and possible physiological roles of the GHS and ghrelin on GH secretion, and finally, the possible therapeutic applications of these compounds are reviewed.
Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.
  • Jose M Garcia, W. Polvino
  • Medicine, Biology
    Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
  • 2009
[News options and preparations in growth hormone therapy].
TLDR
The oral secretagogues have not proved efficacy to be used in clinical practice and the slow- release preparations of GH and GH releasing hormone that could improve the patient's compliance will need to be studied considering long term efficacy and safety.
Ghrelin and growth hormone secretagogues, physiological and pharmacological aspect.
TLDR
It is likely that GHSs, acting as either agonists or antagonists on different pathophysiological processes, might have some other clinical impact and therapeutic potential, at least theoretically ghrelin receptor antagonists could be anti-obesity drugs, as blockers of the orexigenic signal from the gastrointestinal tract to the brain.
Integrating GHS into the Ghrelin System
Oligopeptide derivatives of metenkephalin were found to stimulate growth-hormone (GH) release directly by pituitary somatotrope cells in vitro in 1977. Members of this class of peptides and
Adult growth hormone replacement: current understanding.
  • R. Murray
  • Medicine, Biology
    Current opinion in pharmacology
  • 2003
Recombinant human growth hormone therapy in HIV-associated wasting and visceral adiposity
  • M. Yin, M. Glesby
  • Medicine, Biology
    Expert review of anti-infective therapy
  • 2005
TLDR
Recombinant human growth hormone therapy has a clear dose-dependent impact on trunk and visceral fat in HIV-infected patients with central fat accumulation, resulting in improvements in perception of body image and a beneficial effect on lipid parameters.
...
1
2
...

References

SHOWING 1-10 OF 42 REFERENCES
Growth hormone treatment of adults withgrowth hormone deficiency: results of a 13‐month placebo controlled cross‐over study
TLDR
The study aimed to study the effect of biosynthetlc growth hormone replacement in growth hormone deficient adults and found it to be a positive replacement for GH.
The effect of hexarelin on growth hormone (GH) secretion in patients with GH deficiency.
TLDR
The inability of Hex to stimulate GH secretion in patients with hypothalamic-pituitary disconnection strongly supports the concept that in humans, the GH-releasing effect of GH- releasing peptides is mediated by the hypothalamus.
Hexarelin as a test of pituitary reserve in patients with pituitary disease
TLDR
Hexarelin is a growth hormone‐re releasing peptide with GH‐, ACTH/cortisol‐ and prolactin‐releasing effects which involve both hypothalamic and direct pituitary mechanisms and it was investigated whether it could be used to test GH and ACTH / cortisol reserve in patients with pituitsary disease.
The effect of growth hormone administration in growth hormone deficient adults on bone, protein, carbohydrate and lipid homeostasis, as well as on body composition
OBJECTIVE The effect on bone, protein, carbohydrate and lipid homeostasis as well as body composition of the administration of growth hormone to adult patients with growth hormone deficiency was
Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
TLDR
Oral administration of such GHRP-mimetic compounds may have a role in the treatment of GH deficiency of childhood onset, and the clinical significance of these changes will need to be assessed in longer term studies.
Growth hormone (GH) responses to the combined administration of GH-releasing hormone plus GH-releasing peptide 6 in adults with GH deficiency.
TLDR
Combined administration of GHRH plus GHRP-6 elicited a significant increase in plasma GH levels in about 40% of patients diagnosed with GHD by conventional GH testing, and correlate this response with insulin-like growth factor I levels.
The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats.
TLDR
It is concluded that treatment of adult female rats with the GHSs ipamorelin and GHRP-6 increases BMC as measured by DXA in vivo.
Methylprednisolone does not inhibit the release of growth hormone after intravenous injection of a novel growth hormone secretagogue in rats.
TLDR
It is shown that MP does not disrupt the response of the GH-IGF-I axis to an exogenous stimulus like IPA, and repeated stimulation leads to increases in IGF-I and of body weight gain.
Treatment of adults with growth hormone (GH) deficiency with recombinant human GH.
TLDR
The results show that GH replacement in GHD adults results in marked alterations in body composition, fat distribution, and bone and mineral metabolism and reduces psychiatric symptoms.
Two-month treatment of obese subjects with the oral growth hormone (GH) secretagogue MK-677 increases GH secretion, fat-free mass, and energy expenditure.
TLDR
It is concluded that 2-month treatment with MK-677 in healthy obese males caused a sustained increase in serum levels of GH, IGF-I, and IGF-binding protein-3, and changes in body composition and energy expenditure were of an anabolic nature.
...
1
2
3
4
5
...